News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|December 4, 2020

Lurbinectedin: NCCN Guidelines

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Cervical Cancer-art4stock-stock.adobe.com.jpeg

Never-Screened Cervical Cancer Rates Climb Among US Women

ByGiuliana Grossi

August 27th 2026

Weight loss injections. | Image Credit: ricka_kinamoto - stock.adobe.com

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity

ByGiuliana Grossi

June 15th 2026

FDA approval | Image Credit: Tada Images - stock.adobe.com .jpeg

5 Key Regulatory Shifts From Makary's Era at the FDA

ByPearl Steinzor

May 13th 2026

Marking 10 years since the CDC’s opioid prescribing guidelines, the 2022 update broadens patient care, emphasizes individualized decisions, and aims to reduce opioid-related harms. | Imaged credit: Tada Images - stock.adobe.com

The 10th Anniversary of the CDC's Opioid Prescribing Guidelines: New Evidence and Patient-Centered Decisions

BySabrina McCrear

March 24th 2026

Version 1.2026 of the guidelines emphasizes the necessity of multidisciplinary consultation at centers with specialized expertise for both high-risk and very-high-risk disease. | Image credit: wavebreak3 - stock.adobe.com

Guideline Updates Refine Management for Very High-Risk Squamous Cell Skin Cancer

February 27th 2026

Trending on AJMC

FDA Expands Tirzepatide Label to Reduce Cardiovascular Risk in Type 2 Diabetes

Unvaccinated COVID-19 Infection Tied to Higher Myocarditis Risk

DOJ Abandons Olmstead Defense as Texas v Kennedy Advances

MRI Shows Hypothalamic Atrophy in Narcolepsy Type 1, Sparing Subregion

Back-to-School Vaccines: What Clinicians Need to Know in 2026